期刊
BIOESSAYS
卷 35, 期 3, 页码 281-298出版社
WILEY
DOI: 10.1002/bies.201200053
关键词
automation; cardiomyocytes; drug safety assessment; human embryonic stem cells; human induced pluripotent stem cells
资金
- British Heart Foundation
- Medical Research Council
- Biotechnology and Biological Sciences Research Council
- Engineering and Physical Research Council
- BBSRC [BB/G010390/1, BB/E006159/1, BB/G021821/1] Funding Source: UKRI
- MRC [G0801098, G113/30] Funding Source: UKRI
- Biotechnology and Biological Sciences Research Council [BB/G010390/1, BB/G021821/1, BB/E006159/1] Funding Source: researchfish
- British Heart Foundation [PG/09/027/27141] Funding Source: researchfish
- Engineering and Physical Sciences Research Council [1118928] Funding Source: researchfish
- Medical Research Council [G0801098, G113/30] Funding Source: researchfish
The emphasis in human pluripotent stem cell (hPSC) technologies has shifted from cell therapy to in vitro disease modelling and drug screening. This review examines why this shift has occurred, and how current technological limitations might be overcome to fully realise the potential of hPSCs. Details are provided for all disease-specific human induced pluripotent stem cell lines spanning a dozen dysfunctional organ systems. Phenotype and pharmacology have been examined in only 17 of 63 lines, primarily those that model neurological and cardiac conditions. Drug screening is most advanced in hPSC-cardiomyocytes. Responses for almost 60 agents include examples of how careful tests in hPSC-cardiomyocytes have improved on existing in vitro assays, and how these cells have been integrated into high throughput imaging and electrophysiology industrial platforms. Such successes will provide an incentive to overcome bottlenecks in hPSC technology such as improving cell maturity and industrial scalability whilst reducing cost.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据